monoclonal antibodies

DRUG3 trials

Sponsors

Dana-Farber Cancer Institute, University of Oxford, Centre for the AIDS Programme of Research in South Africa

Conditions

COVID-19HIV/AIDSWaldenstrom's Macroglobulinemia

Phase 1

CAPRISA 095 Study: Phase 1 study to assess the effect of broadly neutralizing monoclonal antibodiesCAP256V2LS and VRC07-523LS combined with antiretroviral therapy on the HIV-1 latent reservoir (NeutART)

Active, not recruitingPACTR202309578224660

Centre for the AIDS Programme of Research in South AfricaHIV/AIDS

Start: 2023-10-23Target: 30Updated: 2026-01-27

Phase 2

Finding Treatments for COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COVID-19 (PLATCOV)

RecruitingNCT05041907

University of OxfordCOVID-19

Start: 2021-09-30End: 2027-01-01Target: 3800Updated: 2026-02-19

Unknown Phase

Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

CompletedNCT00142155

Dana-Farber Cancer InstituteWaldenstrom's Macroglobulinemia

Start: 2002-01-31End: 2007-03-31Target: 300Updated: 2011-06-27

Related Papers

LC-MS/MS Method Validation for Quantification of Nirmatrelvir in Human Plasma.

2025-11-17

Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

2025-10-101 citations

Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV).

2025-01-183 citations

Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).

2024-04-2410 citations

Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial.

2024-01-1518 citations

Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.

2023-09-2852 citations

Clinical Antiviral Efficacy of Remdesivir in Coronavirus Disease 2019: An Open-Label, Randomized Controlled Adaptive Platform Trial (PLATCOV)

The Journal of Infectious Diseases2023-07-1924 citations

Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)

eLife2023-02-0618 citations